Make Faster, Smarter Research Decisions
These organoid platform features help you reduce the risk of clinical failure by
generating data that is more predictive, reproducible, and clinically relevant.
Turn organoid complexity into speed with assay-ready organoid batches that deliver CTG efficacy data in only 3 weeks.
Largest commercially available organoid (PDO and PDXO) biobank - with matched in vivo capabilities.
Get fully characterized, QC-verified models and assays designed for consistent, reproducible results. Models and assays are held to the highest industry standards, with high assay reproducibility and PDXO models free of mouse-derived content, reducing uncertainty and helping prevent costly downstream surprises.
Protect study integrity with a level of genomic quality control not typically available from standard profiling approaches. SNP-based profiling delivers up to 10× greater sensitivity than STR-based profiling, enabling more sensitive detection of contamination and helping ensure the integrity of every biobank sample.
Trust that results reflect patient biology because our proprietary culture methods, built on exclusive Clevers Lab HUB protocols, preserve clinical fidelity that standard systems lose.
Across 35+ indications including (patient-matched) normal and primary + metastatic models, and resistant/pre-treated models.
Platform Applications
Test candidate efficacy, safety, side effects, and pharmacokinetic properties as well as mechanism of action.
Evaluate safety and toxicity profiles using healthy organoids developed from non transformed cells.
Capture disease relevance and patient population heterogeneity with disease modeling, including models of drug resistance.
Identify your target patient population before entering the clinical trials.
Determine potential biomarkers of therapeutic response with companion diagnostics.
Study Options
Select models and evaluate efficacy and multi-drug combination strategies.
Identify responder and non-responder tumor models. Leverage high content services to produce highly comprehensive morphology readouts in both 2D and 3D models. Use multifactorial data for downstream lead ID and decision-making.
Phenotypically screen up to thousands of compounds. Layer and score drug effects with image mediated screens.
Benefit from the only immuno-oncology platform incorporating patient-relevant 3D in vitro models co-cultured with non-autologous immune cells.
